336 related articles for article (PubMed ID: 33601065)
1. Nanomedicines for the treatment of glaucoma: Current status and future perspectives.
Zhai Z; Cheng Y; Hong J
Acta Biomater; 2021 Apr; 125():41-56. PubMed ID: 33601065
[TBL] [Abstract][Full Text] [Related]
2. Glaucoma: Current treatment and impact of advanced drug delivery systems.
Yadav KS; Rajpurohit R; Sharma S
Life Sci; 2019 Mar; 221():362-376. PubMed ID: 30797820
[TBL] [Abstract][Full Text] [Related]
3. Nanoscale Drug Delivery Systems for Glaucoma: Experimental and
Sharma S; Bhatia V
Curr Top Med Chem; 2021; 21(2):115-125. PubMed ID: 32962618
[TBL] [Abstract][Full Text] [Related]
4. Technological Advances in a Therapy of Primary Open-Angle Glaucoma: Insights into Current Nanotechnologies.
Zembala J; Forma A; Zembala R; Januszewski J; Zembala P; Adamowicz D; Teresiński G; Buszewicz G; Flieger J; Baj J
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762739
[TBL] [Abstract][Full Text] [Related]
5. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
6. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
[TBL] [Abstract][Full Text] [Related]
7. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
8. Latanoprost niosomes as a sustained release ocular delivery system for the management of glaucoma.
Fathalla D; Fouad EA; Soliman GM
Drug Dev Ind Pharm; 2020 May; 46(5):806-813. PubMed ID: 32281424
[No Abstract] [Full Text] [Related]
9. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy.
Rahman M; Akhter S; Ahmad J; Ahmad MZ; Beg S; Ahmad FJ
Expert Opin Drug Deliv; 2015 Apr; 12(4):635-52. PubMed ID: 25439967
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine.
Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
Br J Ophthalmol; 2014 Apr; 98(4):427-31. PubMed ID: 24246373
[TBL] [Abstract][Full Text] [Related]
12. [Aiming for zero blindness].
Nakazawa T
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
[TBL] [Abstract][Full Text] [Related]
13. Newer therapeutic vistas for antiglaucoma medicines.
Kaur IP; Kakkar S
Crit Rev Ther Drug Carrier Syst; 2011; 28(2):165-202. PubMed ID: 21663575
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology for Medical and Surgical Glaucoma Therapy-A Review.
Occhiutto ML; Maranhão RC; Costa VP; Konstas AG
Adv Ther; 2020 Jan; 37(1):155-199. PubMed ID: 31823205
[TBL] [Abstract][Full Text] [Related]
15. Advances and challenges in nanocarriers and nanomedicines for veterinary application.
Carvalho SG; Araujo VHS; Dos Santos AM; Duarte JL; Silvestre ALP; Fonseca-Santos B; Villanova JCO; Gremião MPD; Chorilli M
Int J Pharm; 2020 Apr; 580():119214. PubMed ID: 32165220
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicines: A Focus on Nanomaterials as Drug Delivery System with Current Trends and Future Advancement.
Pandey J; Dubey R; Kate A; Prasad B; Sinha A; Mishra MS
Drug Res (Stuttg); 2022 Sep; 72(7):355-366. PubMed ID: 35636435
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines for the treatment of hematological malignancies.
Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
[TBL] [Abstract][Full Text] [Related]
18. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
19. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders.
Muthu MS; Singh S
Nanomedicine (Lond); 2009 Jan; 4(1):105-18. PubMed ID: 19093899
[TBL] [Abstract][Full Text] [Related]
20. Current nanotechnological strategies for treating glaucoma.
Goyal G; Garg T; Rath G; Goyal AK
Crit Rev Ther Drug Carrier Syst; 2014; 31(5):365-405. PubMed ID: 25271557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
